Diabetes Technology & Therapeutics Publishes Retrospective Analysis Detailing Impact of Threshold Suspend in Addressing Hypoglycemia
DUBLIN - Medtronic plc (NYSE:MDT) today announced results of a retrospective analysis based on real-world data from over 20,000 MiniMed® 530G users, which found that the pump's Threshold Suspend feature reduced hypoglycemia, especially at night, without significantly increasing hyperglycemia. The results, titled "Retrospective Analysis of the Real-World Use of the Threshold Suspend Feature of Sensor-Augmented Insulin Pumps," were published online, ahead of print, in Diabetes Technology & Therapeutics.
"Hypoglycemia is a serious concern for people with diabetes, especially when it occurs at night because sleep blunts awareness of hypoglycemia's symptoms," said Francine R. Kaufman, M.D., chief medical officer and vice president of global, clinical and medical affairs for Medtronic Diabetes. "The present analysis showed that when people with diabetes use the Threshold Suspend feature on the MiniMed 530G system in the real world, they experience the same reduction in hypoglycemia that was observed in research trials."
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
The MiniMed 530G system is the first and only system to offer Threshold Suspend, which suspends insulin delivery for up to two hours when the sensor glucose value reaches a pre-set low level and if the user is unable to respond to the Threshold Suspend alarm. Results of the analysis include:
Overall hypoglycemia was reduced by 69 percent: Patient-days where the Threshold Suspend feature was enabled showed 69 percent less time in hypoglycemia (sensor glucose values <=50 mg/dL) compared to patient-days when the feature was not enabled (0.64% vs. 2.09%, respectively, p<0.001).
Night-time hypoglycemia was reduced by 73 percent: The reduction in hypoglycemia seen on Threshold Suspend-enabled days was more pronounced during nighttime than during daytime hours. A 73 percent reduction in time in hypoglycemia occurring at night was seen on patient-days when the Threshold Suspend feature was on (percent of sensor glucose values <=50 mg/dL, sensor glucose percentages equivalent to 17 minutes/night when Threshold Suspend was off vs. 5 min/night for when Threshold Suspend was on, p<0.001).
"The Threshold Suspend feature on the MiniMed 530G system has been a critical milestone toward Medtronic's goal to develop a fully automated artificial pancreas," said Alejandro Galindo, vice president and general manager of the Intensive Insulin Management business at Medtronic. "Our integrated insulin delivery systems are the only ones that can take action, mimicking the functioning of a healthy pancreas, to help people with diabetes enjoy greater freedom and better health."
